Roquefort Therapeutics plc (LON:ROQ – Get Free Report)’s share price fell 10.5% during mid-day trading on Wednesday . The stock traded as low as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). 19,641,881 shares changed hands during mid-day trading, an increase of 447% from the average session volume of 3,591,296 shares. The stock had previously closed at GBX 1.90 ($0.02).
Roquefort Therapeutics Trading Down 15.7 %
The company has a market capitalization of £2.04 million, a PE ratio of -1.32 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The firm’s 50 day moving average is GBX 2.55 and its 200 day moving average is GBX 3.52.
Insider Activity
In other Roquefort Therapeutics news, insider Stephen Paul West purchased 400,000 shares of Roquefort Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,535.99). Insiders own 60.40% of the company’s stock.
About Roquefort Therapeutics
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Recommended Stories
- Five stocks we like better than Roquefort Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Tesla Stock: Has the Mother of All Comebacks Begun?
- There Are Different Types of Stock To Invest In
- Palantir Setting Up to Be a Big Winner With New Defense Spending
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
